Paul, Weiss, Rifkind, Wharton & Garrison LLP announced today that Robert F. Masella will join the firm in New York as a partner in the M&A Group within the Corporate Department. A distinguished M&A lawyer and former Bank of America Merrill Lynch managing director, Masella has decades of experience advising public and private companies, corporate boards, private equity funds, and financial institutions on complex domestic and cross-border M&A transactions across sectors, with a particular emphasis on life sciences.
“I have worked closely with Rob over many years,” said Scott Barshay, chairman of Paul, Weiss. “He is a spectacular M&A lawyer and advisor, and I couldn’t be happier that he is joining Paul, Weiss.”
“Rob is one of the very best M&A lawyers and a market leader in life sciences,” said Krishna Veeraraghavan, global co-head of M&A at Paul, Weiss. “He is an exceptional addition to our team and will create great value for our clients.”
Masella has advised on some of the most significant U.S. and cross-border transactions. His practice includes public and private M&A, dual-track M&A/IPO processes, joint ventures, option agreements, licensing and collaboration agreements, and spin-offs. His broad experience spans many industries with a particular emphasis on life sciences, which he will help drive at Paul, Weiss. Masella’s practice also includes advising boards of directors on corporate governance, shareholder activism, fiduciary duties, and conflict-of-interest matters.
“Paul, Weiss’ robust platform and deep life sciences experience make it the ideal home for my practice,” Masella said. “I am excited to join such a talented and exceptional team.”
Masella’s most recent representations include advising SpringWorks Therapeutics in its acquisition by Merck KGaA; Versanis Bio in its acquisition by Eli Lilly; Color Wow in its acquisition by L’Oréal; Proteologix in its acquisition by Johnson & Johnson; Ironshore Therapeutics in its acquisition by Collegium Pharmaceutical; Teleflex in its acquisition of Biotronik’s Vascular Intervention business; Ally Bridge Group in multiple investments; Thomson Reuters in multiple acquisitions; and leading financial institutions in multiple transactions.
Masella earned a B.A., magna cum laude, from the College of William & Mary and the London School of Economics, and a combined J.D./M.B.A., magna cum laude, from the University of Pennsylvania Law School and The Wharton School. He is a member of several boards, including TheChurch, a non-profit art center, exhibition space and artist residency. He has also been involved in Law360’s Life Sciences Editorial Advisory Board, the Business Law Partner Advisory Board of Thomson Reuters Accelus, the National Advisory Committee of the Colonial Williamsburg Foundation, the New York Bar Association’s Committee on Mergers & Acquisitions and Corporate Control Contests, and the New York Bar Association’s Corporation Law Committee.
The Paul, Weiss Mergers & Acquisitions Practice works with leading private equity firms and many of the world’s largest, most prominent publicly traded and privately held companies, as well as financial advisors and other financial institutions and investors, on the full range of business-critical transactions.